Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01282502 · ClinicalTrials.gov registry record · Phase 1
Midostaurin (PKC412) for Locally Advanced Rectal Cancer
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT01282502: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01282502 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01282502, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This study combines midostaurin (PKC412) with radiation and a standard chemotherapy drug call 5-Fluorouracil (5-FU) for subjects with advanced rectal cancer. Midostaurin is a type of kinase inhibitor which works by blocking proteins associated with cancer cell growth. Previous studies also suggest that midostaurin may help increase the effectiveness of radiation therapy. In this research we are looking for the highest dose of midostaurin that can be given safely in combination with standard chemoradiation.
Interventions
- DRUG Midostaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2011-08 |
| Est. Completion | 2018-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01282502
The ClinicalTrials.gov registry entry for NCT01282502 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Midostaurin is the first listed.
NCT01282502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01282502 about?
NCT01282502 is a clinical study titled "Midostaurin (PKC412) for Locally Advanced Rectal Cancer". This study combines midostaurin (PKC412) with radiation and a standard chemotherapy drug call 5-Fluorouracil (5-FU) for subjects with advanced rectal cancer. Midostaurin is a type of kinase inhibitor which works by blocking proteins associated with cancer cell growth. Previous studies also suggest t...
What is the current status of trial NCT01282502?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2011-08. Estimated completion is 2018-12.
What interventions are being tested in trial NCT01282502?
The interventions under investigation include: Midostaurin (DRUG).
Who is sponsoring clinical trial NCT01282502?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.